German biotech company BioVisioN AG signed an agreement with Abbott, a global, broad-based health care company, to collaborate on research relating to the discovery of novel biomarkers for lung cancer.
According to the agreement, BioVisioN will analyze biological samples provided by Abbott to discover tumour biomarkers. Biomarkers play an important role in new strategies for the early diagnosis and effective treatment of diseases. Under the agreement, BioVisioN will receive research payments and, if successful, milestones and royalty payments.
BioVisioN AG specializes in the identification of disease-relevant peptides and proteins using Peptidomics and Differential Peptide Display.